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Abstract
Objective
Ovarian cancer is the leading cause of death among gynecologic malignancies. This is
partly due to a non-durable response to chemotherapy. Prediction of resistance to chemo-
therapy could be a key role in more personalized treatment. In the current study we aimed to
examine if microRNA based predictors could predict resistance to chemotherapy in ovarian
cancer, and to investigate if the predictors could be prognostic factors for progression free
and overall survival.
Methods
Predictors of chemotherapy-resistance were developed based on correlation between
miRNA expression and differences in measured growth inhibition in a variety of human can-
cer cell lines in the presence of Carboplatin, Paclitaxel and Docetaxel. These predictors
were then, retrospectively, blindly validated in a cohort of 170 epithelial ovarian cancer
patients treated with Carboplatin and Paclitaxel or Docetaxel as first line treatment.
Results
In a multivariate cox proportional analysis the predictors of chemotherapy-resistance were
not able to predict time to progression after end of chemotherapy (hazard ratio: 0.64, 95%
CI: 0.36–1.12, P = 0.117). However, in a multivariate logistic analysis, where time to pro-
gression was considered as either more or less than 6 months, the predictors match clinical
observed chemotherapy-resistance (odds ratio: 0.19, 95% CI: 0.05–0.73, P = 0.015). Nei-
ther univariate nor multivariate, time-dependent, cox analysis for progression free survival
(PFS) or overall survival (OS) in all 170 patients showed to match predicted resistance to
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Conclusion
In the current study, microRNA based predictors of chemotherapy-resistance did not dem-
onstrate any convincing correlation to clinical observed chemotherapy-resistance, progres-
sion free survival, or overall survival, in patients with epithelial ovarian cancer. However the
predictors did reflect relapse more or less than 6 months.
Introduction
Ovarian cancer (OC) remains the most lethal gynecologic malignancy in the western world,
and the 5th most common cause of cancer death for women [1–3]. The majority of patients
will be diagnosed in advanced stages (FIGO stage III-IV) where the 5-year overall survival rate
is only 15–30% in Denmark [4]. This is primarily due to the late diagnosis, and despite
improvements in combined chemotherapy; acquisition of resistance to chemotherapy is a
major contributor to the low 5-year survival rate. Standard treatment of patients with OC is
primary debulking surgery followed by adjuvant platinum-based combination chemotherapy
[5]. Although the majority of patients initially respond well to chemotherapy, most of them
will eventually experience relapses and eventually develops resistance to platinum based che-
motherapy [4, 6–8]. Therefore there is an unmet need for biomarkers that can predict patients’
resistance to chemotherapy, spare patients from in-effective, toxic agents, and optimize treat-
ment for each individual patient.
MicroRNAs (miRNAs) are small, 21–23 nucleotides long, non-coding RNA molecules that
regulate gene expression by binding to the 3’-untranslated region of target genes that either
induces mRNA degradation or represses translation of the protein [9, 10]. During the last
decade it has been confirmed that miRNAs can function as tumor suppressors and oncogenes
and play an important role in cancer [11]. Several studies have also identified miRNAs to be
abnormally expressed in OC [12–15].
Currently there are no methods available for prediction of the individual patients’ resistance
to chemotherapy, which is a key role in the development of personalized medicine. In this
study we retrospectively validated miRNA based predictors, developed from the miRNA
expression profile of a panel of cell lines that has been tested for their sensitivity to different
chemotherapeutics. The aim of the study was to investigate if miRNA profiles can predict the
sensitivity of platinum alone or the combined treatment of platinum and taxanes.
Material and methods
Patients and material
All patients for the current study were recruited from the Pelvic Mass study. The Pelvic Mass
study was initiated in September 2004 at the Gynecologic Department, Rigshospitalet, Den-
mark. The study is a prospective ongoing study, with the intent to identify diagnostic and
prognostic factors for OC. Patients with a potential malignant pelvic mass are invited to partic-
ipate in the study, when admitted to Rigshospitalet for surgery. If radical surgery is considered
possible a gynecologic oncologist operates the patient, and except for stage IA/IB low grade, all
patients are subsequently offered chemotherapy. All histologic diagnoses are given by a
MicroRNA and chemotherapy prediction in ovarian cancer
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pathologist specialized in gynecologic pathology, and the tissue is handled and stored by the
Danish CancerBiobank [16]. Clinical information from each patient is registered online in the
nationwide Danish Gynecological Cancer Database that covers information on more than
95% of all Danish patients diagnosed with ovarian, endometrial, vulva and cervical cancers [4].
The database further includes patient’s 10-digit national personal identification number,
which enables linkage to other national registries. Information on death of any cause was
obtained from the Civil Registration System [17].
Inclusion criteria were: OC with epithelial histology, primary surgery followed by treatment
with a minimum of two cycles of adjuvant chemotherapy. Exclusion criteria were: Non epithe-
lial OC, carcinosarcomas, neoadjuvant chemotherapy, no chemotherapy due to FIGO stadium
IA, less than 2 series of adjuvant chemotherapy, patients who refrained from treatment, con-
comitant cancer disease, postoperative death or a poor medical condition that contraindicated
treatment with chemotherapy, or insufficient tissue for analysis.
Progression Free Survival (PFS) was defined as the time from primary surgery until relapse,
progressive disease (PD) or death of any cause which ever occurred first. Relapse and PD were
defined from the best clinical evaluation, on the basis of CT/MRI/PET-CT scans, serum
CA125 and patients’ symptoms. In 18 cases, where second line chemotherapy was initiated,
but no information on relapse or PD was registered, start date of second line chemotherapy
was considered as relapse or PD. Chemotherapy-resistance was defined as relapse or PD
within six months after chemotherapy. If patients developed PD during treatment, or within 4
weeks after last cycle, they were considered chemotherapy-refractory. Patients were considered
chemotherapy-sensitive if they had no relapse or PD, or if relapse or PD occurred more than 6
months after end of first line chemotherapy. Time from end of first line chemotherapy until
relapse, PD or start of second line chemotherapy was designated time to progression and both
the actual time, and time categorized as more, or less than 6 months, were used for statistical
analyses of resistance to chemotherapy. Cause of death was defined as either, death of gyneco-
logic cancer, or death of other causes. Patients were followed from date of surgery until death
of any cause, emigration, or until January 17, 2015, which ever came first.
Ethics statements
All patients included in the Pelvic Mass study are informed both in writing and orally and the
commitment and participation is given with a written consent. The Danish Ethical Committee
approves the Pelvic Mass protocol according to the rules of the International Conference on
Harmonization/Good Clinical Practice (ICH/GCP) recommendations and the Helsinki and
Tokyo conventions (KF01-227/03 and KF01-143/04).
Microarray analysis
The miRNA analyses were made on formalin-fixed paraffin embedded (FFPE) tissue, where
one slice of 20μm thickness from each patient was used. The tumor cell content was previously
estimated from hematoxylin and eosin staining by a pathologist, specialized in gynecologic
pathology, and was more than 50% in all of the tumors. miRNA was extracted using a total
nuclei acid isolation kit for FFPE, RecoverAll (Ambion, Inc 2130 Woodward St. Austin, TX).
miRNA was then labeled using FlashTag HSR™ Biotin RNA Labeling Kit (Genisphere, PA) and
analyzed using GeneChip1 miRNA arrays (Affymetrix, CA).
miRNA predictor developed on in vitro assay
To evaluate the correlation between miRNA expression and drug sensitivity, growth inhibition
(GI50) vectors of the NCI60 cell line panel subjected to Carboplatin, Paclitaxel and Docetaxel
MicroRNA and chemotherapy prediction in ovarian cancer
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were downloaded from the Developmental Therapeutics Program of the U.S National Can-
cer Institute’s web site. The NCI60 cell line panel consists of 60 different human cancer cell
lines, including OC, and was developed as an in-vitro drug discovery tool for research in
anti-cancer drug screening, and today function as a service screen tool for the cancer
research community [18]. Correlation between miRNA expression and drug sensitivity in
the cell lines was calculated for each miRNA–drug combination as previously described by
Winther et al. [19]. miRNAs with a correlation above 0.25 (positively correlated miRNAs) or
below -0.25 (negatively correlated miRNAs) were retained for each treatment, and then com-
bined in order to predict sensitivity to combination treatment. Hence, three miRNA sensitiv-
ity profiles were developed in which miRNA expression levels were correlated to the
sensitivity of the treatment regimens.
Blind prediction of chemotherapy-resistance in clinical samples
The normalized expression of each miRNA in a sensitivity profile was used to predict sensi-
tivity by turning the miRNA expression levels into a single prediction score. Hence, for each
patient, sensitivity to the received treatment strategy was calculated as the difference between
the average of positively correlated miRNAs and the average of negatively correlated miR-
NAs (prediction score = mean (positively correlated miRNAs)–mean (negatively correlated
miRNAs)). Each miRNA in the profile was given equal weight. Next, the prediction score
was normalized to a scale from 0 to 100 by a linear transformation of the prediction score of
all patient samples. A score of zero meant least sensitive and a score of 100 most sensitive to
the given treatment. For each patient, a score of predicted sensitivity to the received treat-
ment strategy was calculated, while information of their clinical resistance to chemotherapy
was blinded.
Statistical analysis
The statistical analyses were performed according to an analysis plan included in the protocol
finalized before the study.
Predictors of sensitivity for the drugs Carboplatin, Paclitaxel, Docetaxel, were combined
and applied according to the treatment each patient had received. The sensitivity predictor
was treated as a continuous variable and for statistical analysis divided by 50 resulting in odds
ratios and hazard ratios for a 50 percent point difference in level.
For estimation of survival probabilities, Kaplan-Meier analysis was calculated by the tertiles
of the predictor. The assumptions of proportionality and linearity were assessed with cumu-
lated martingale residuals, and the assumptions were fulfilled. For estimation of median fol-
low-up time, reverse Kaplan-Meier method was used.
Cox proportional hazards regression was used for both univariate and multivariate analysis
of time to progression, progression free survival (PFS), and death (overall survival (OS)). Can-
cer specific survival was estimated with death of other causes as a competing risk [20].
Secondary univariate and multivariate analysis of chemotherapy-resistance was performed
with logistic regression for time to progression categorized as more or less than 6 months. The
multivariate analyses were adjusted for age, FIGO stage, histologic subtype and macroradical
surgery. Preliminary analyses of interactions between relevant clinical parameters were
performed.
Statistical significance was defined by a P value 0.05. The statistical analyses were per-
formed using SAS statistical software packaged (version 9.4, Cary N.C. USA), R (v 3.1.0 R
Development Core team, Vienna, Austria, http://www.R-project.org), and IBM SPSS statistical
software version 19.
MicroRNA and chemotherapy prediction in ovarian cancer
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Results
Baseline characteristics
The first 246 patients consecutively included in the Pelvic Mass study, diagnosed with epithe-
lial OC, were recruited for the study. 76 patients were excluded based on previously mentioned
exclusion criteria, and were distributed as follows: Non epithelial OC (n = 2), Carcinosarcomas
(n = 5), neoadjuvant chemotherapy (n = 15), no chemotherapy due to FIGO stadium IA
(n = 8), less than 2 series of adjuvant chemotherapy (n = 3), patients who refrained from treat-
ment (n = 4), concomitant cancer disease (n = 3), postoperative death (n = 5), a poor medical
condition that contraindicated treatment with chemotherapy (n = 7), or insufficient tissue for
analysis (n = 24). A total of 170 patients were eligible for inclusion in this study (S1 Clinical
Data). There were no statistically significant difference between the 24 patients excluded due
to insufficient tissue material, and the 170 patients included in the study according to age
(p = 0.41), FIGO stage (p = 0.49) and histologic type (p = 0.19). For the patients included in
the study, histologic diagnoses were as follows; 143 (83.6%) patients were diagnosed with
serous carcinoma (low-grade: 3 (2%), high-grade: 140 (98%)), 10 (5.8%) patients with endome-
trioid carcinoma, 9 (5.3%) patients with clear cell carcinoma and 9 (5.3%) patients with mucin-
ous carcinoma (Table 1). After primary debulking surgery, 81 (47.6%) patients had obtained
macroradical surgery. Subsequently 165 (96.5%) patients received chemotherapy with the
combination of Carboplatin and Docetaxel. 5 (2.9%) patients received single drug treatment
with Carboplatin and one patient (0.6%) received treatment with the combination of Carbo-
platin and Paclitaxel.
At end of follow up a total of 114 (67.1%) patients had died, and 56 patient were still alive
(32.9%). 126 (74.1%) patients had experienced relapse or PD, and 44 (25.9%) patients were
alive without relapse. Median follow-up time was 86.2 months (range: 61.1–127.4), and
median OS was 51.1 months (95% CI: 43.9–60.8). Out of the 170 patients, 81 (47.6%) patients
obtained macroradical surgery. Patients who were sensitive to chemotherapy amounted 124
(72.9%). Twenty-six patients (15.2%) were resistant to chemotherapy and twenty patients
(11.8%) were considered chemotherapy-refractory (Table 1).
Prediction of chemotherapy-resistance and survival
The miRNAs that demonstrated the best correlation with sensitivity were identified, and
selected for use in development of a prediction score for each patient. The miRNAs used for
the prediction are listed in Table 2.
The primary univariate and multivariate cox proportional regression analyses, of the pro-
gression scores modelling time to progression, did not demonstrate a significant association
(Univariate hazard ratio (HR): 0.99, 95% CI: 0.62–1.59, p = 0.97. Multivariate HR: 0.64, 95%
CI: 0.36–1.12, p = 0.117), Table 3.
The secondary univariate logistic regression analysis in prediction of chemotherapy-resis-
tance was not significant (OR 0.47 (95% CI: 0.17–1.30), AUC = 60%, p = 0.15). However the
multivariate logistic regression analysis, adjusted for age, FIGO stage, histologic subtype and
macroradical surgery, showed a significant correlation between the prediction score and che-
motherapy-resistance more or less than 6 months (OR 0.19 (95% CI: 0.05–0.73) p = 0.0152),
Table 4.
Univariate cox proportional hazards model for survival was not statistically significant
(PFS: HR 1.0 (95% CI: 0.62–1.60) p = 0.10; OS: HR 0.97 (95% CI 0.58–1.61) p = 0.90), cancer
specific survival (p = 0.76)). Multivariate cox regression analyses for prediction of survival
showed a trend towards longer survival for higher values of the prediction score, but no
MicroRNA and chemotherapy prediction in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174300 March 23, 2017 5 / 15
significant association was demonstrated (PFS: HR 0.69 (95% CI: 0.40–1.19) p = 0.183; OS:
0.76 (95% CI: 0.42–1.40) p = 0.386), Table 5.
Inclusion of menopausal status in the multivariate analyses did not show to be significant
for any of the endpoints time-to-progression from end of last chemotherapy, chemotherapy-
resistance, PFS or OS, (p-values: 0.86, 0.77, 0.73, 0.87) and age showed to be more associated
with outcome. Therefore menopausal status was not included in the multivariate analyses.
Discussion
As the gynecologic cancer with the poorest prognosis, OC is an important disease where con-
tinuous research that could improve prognosis for the patients, remains an import goal.
Despite most patient respond well to first line chemotherapy, the majority eventually develop
resistance to the treatment. A rational approach to identify patients, who will respond to a
given chemotherapy before initiation of the treatment, could aid in the more personalized
medicine and potentially improve survival of the patients.
In the current study prediction scores of resistance to combinations of Carboplantin, Doce-
taxel and Paclitaxel were developed in 170 OC patients based on their tumor tissue miRNA
Table 1. Baseline characteristics for 170 EOC patients.
Median age at diagnosis 63.9 (IQR: 54.2–72.5)
Median OS in months 51.1 (95% CI: 43.9–60.8)
Histologic type
Serous adenocarcinoma 143 (84.1%)
Mucinous adenocarcinoma 9 (5.3%)
Edometrioid adenocarcinoma 9 (5.3%)
Clear Cell adenocarcinoma 9 (5.3%)
FIGO stage
I 22 (12.9%)
II 18 (10.6%)
III 109 (64.1%)
IV 21 (12.4%)
Histologic grade1
1 12 (7.1%)
2 95 (55.9%)
3 62 (36.5%)
Unknown2 1 (0.6%)
Residual tumor after surgery
0 (macroradical surgery) 81 (47.6%)
< 1 cm 28 (16.5%)
> 1 cm 2 cm 20 (11.8%)
> 2 cm 41 (24.1%)
Time to progression
> 6 months 124 (72.9%)
 6 months 26 (15.3%)
Chemotherapy-refractory 20 (11.8%)
1Grade 1 = well differentiated, Grade 2 = moderately differentiated, Grade 3 =
2The pathologists were not able to determine grade due to necrotic tissue destruction.
FIGO = International Federation of Gynecology and Obstetrics, OS = overall survival, IQR = interquartile
range.
https://doi.org/10.1371/journal.pone.0174300.t001
MicroRNA and chemotherapy prediction in ovarian cancer
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Table 2. List of miRNAs used for prediction of response to chemotherapy.
Positive Negative
Drug
Carboplatin hsa-miR-124_st hsa-miR-10a_st
hsa-miR-143_st hsa-miR-183_st
hsa-miR-1271_st hsa-miR-192-star_st
hsa-miR-342-3p_st hsa-miR-192_st
hsa-miR-370_st hsa-miR-194_st
hsa-miR-433_st hsa-miR-200a-star_st
hsa-miR-654-3p_st hsa-miR-200a_st
hsa-miR-758_st hsa-miR-200b-star_st
U55_x_st hsa-miR-200b_st
hsa-miR-200c-star_st
hsa-miR-203_st
hsa-miR-29b_st
hsa-miR-30b_st
hsa-miR-30d_st
hsa-miR-429_st
hsa-miR-625_st
hsa-miR-7_st
Paclitaxel hsa-miR-106b-star_st HBII-85-29_st
hsa-miR-1228_st hsa-let-7e_st
hsa-miR-185_st hsa-miR-125a-5p_st
hsa-miR-188-5p_st hsa-miR-130a_st
hsa-miR-18b_st hsa-miR-193b_st
hsa-miR-20b_st hsa-miR-22_st
hsa-miR-25_st hsa-miR-27a_st
hsa-miR-320c_st hsa-miR-29a_st
hsa-miR-320d_st hsa-miR-29b_st
hsa-miR-362-5p_st hsa-miR-30a-star_st
hsa-miR-500-star_st hsa-miR-30a_st
hsa-miR-500_st hsa-miR-30c-2-star_st
hsa-miR-501-3p_st hsa-miR-30c_st
hsa-miR-502-3p_st hsa-miR-34a_st
hsa-miR-532-3p_st hsa-miR-34b-star_st
hsa-miR-532-5p_st hsa-miR-34c-3p_st
hsa-miR-652_st hsa-miR-34c-5p_st
hsa-miR-766_st
Docetaxel hsa-miR-1307_st HBII-438A_s_st
hsa-miR-505_st HBII-85-11_st
hsa-miR-769-3p_st HBII-85-15_x_st
hsa-miR-769-5p_st HBII-85-23_x_st
HBII-85-29_st
HBII-85-29_x_st
hsa-miR-184_st
hsa-miR-29a_st
hsa-miR-29b_st
hsa-miR-34a_st
hsa-miR-34c-3p_st
(Continued )
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expression, and the global miRNA expression and growth response of the NCI60 cell line
panel. In the univariate and multivariate analyses of chemotherapy-resistance modelling time
to progression, adjusted for relevant prognostic factors, the miRNA based predictors were
insignificant predictors of chemotherapy-resistance.
In secondary analyses, when chemotherapy-resistance was defined as time to progression
or death more or less than 6 months, the miRNA predictors showed an association with resis-
tance in multivariate logistic analysis, adjusted for relevant clinical factors (p = 0.015).
For PFS and OS a trend towards higher values of the prediction scores were associated with
longer PFS and OS, however the results were insignificant.
The current method used for development of the miRNA predictor, is based on a novel bio-
informatic approach that has been described in two former, published studies [19, 21]. In the
first study, miRNA predictors of sensitivity to CHOP (Cyclophosphamide, Doxorubicin, Vin-
cristine and Prednisone) and CHOEP (Cyclophosphamide, Doxorubicin, Vincristine, Etopo-
side and Prednisone) were developed and blindly validated in a cohort of 116 patients with
diffuse large B-cell lymphoma. The study demonstrated that the miRNA predictors were able
to predict the patients sensitivity to CHOP and CHOEP [21]. The most recent study investi-
gated if miRNA based predictors of sensitivity to Cisplatin, Epirubicine and Capecitabine were
predictive of survival in patients with gastroesophageal cancer, and in both univariate and
multivariate analyses they found the miRNA profiles, predictive for the chemotherapeutics, to
be independently associated with overall and disease free survival [19].
Prediction of OC patients’ sensitivity to chemotherapy is an important factor for improve-
ment of prognosis. Currently, there are no molecular methods that accurately can predict che-
motherapy-sensitivity, and guide clinicians in the selection of the potentially most effective
therapy for the individual patient with OC.
miRNAs have in previous studies shown to be possible biomarkers for prediction of sensi-
tivity to chemotherapy. The most frequently reported miRNAs shown to be associated with
chemotherapy-sensitivity are the let-7 and the miR-200 families [22–24]. Yang et al. found that
let-7i was significantly deregulated in chemotherapy-resistant patients with EOC, illustrating
the let-7 family tumor suppressor function that also has been demonstrated in others studies
[22, 25, 26]. However, in another study, identifying miRNAs to be altered in human OC resis-
tant cell lines, let-7e showed to be upregulated in Paclitaxel-resistant (A2780TAX) cells, but
downregulated in other, both Paclitaxel- and Cisplatin-resistant, cell lines, whereas miR-30c
was downregulated in all Paclitaxel- and Cisplatin-resistant cell lines. Also miR-130a showed
to be downregulated in all resistant cell lines, and suggested to exert its effect by targeting
M-CSF, known to enhance invasiveness and metastasis in OC [23]. In our study, let-7e, miR-
30c and miR-130a were negatively correlated to Paclitaxel, but only one patient in our study
was treated with Paclitaxel. The studies of the miR-200 family in association with drug-resis-
tance in OC are conflicting. The miR-200 family is an important regulator of epithelial-to-
Table 2. (Continued)
Positive Negative
Drug
hsa-miR-34c-5p_st
hsa-miR-424-star_st
Both positively and negatively miRNAs that were correlated to drug sensitivity of each drug are presented.
Positive = correlation above 0.25. Negative = correlation below -0.25.
MiRNAs marked in bold represent the miRNAs that are identified for both Paclitaxel and Docetaxel.
https://doi.org/10.1371/journal.pone.0174300.t002
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mesenchymal transition (EMT) that has a central role in cancer cell invasion, migration and
drug resistance in several types of cancers [27–32]. Leskela et al. showed that patients with low
expression of miR-200c was associated with high b-tubulin III protein content and lack of
complete response to Platinum/Taxane-based chemotherapy [33]. In resemblance, two other
studies have demonstrated that upregulation of miR-200c sensitized OC cell lines to Carbopla-
tin and Paclitaxel [27, 29]. In other studies, upregulation of miR-200a and miR-141 has been
Table 3. Multivariate cox analyses of the miRNA prediction score modelling time to progression from
end of last chemotherapy (n = 170).
HR 95% CI P-value
Prediction score 0.64 0.36–1.12 0.117
Age 1.11 0.94–1.31 0.204
FIGO stage
I 0.09 0.02–0.34 0.0004
II 0.53 0.22–1.28 0.159
III 0.94 0.53–1.66 0.823
IV - - -
Histologic type
Serous adenocarcinoma 0.55 0.19–1.61 0.276
Mucinous adenocarcinoma 0.48 0.11–2.09 0.325
Endometriod adenocarcinoma 0.15 0.03–0.89 0.037
Clear cell adenocarcinoma - - -
Macroradical surgery (yes/no) 0.32 0.21–0.49 <0.001
HR = hazard ratio, 95% CI = 95% confidence interval, FIGO = International Federation of Gynecology and
Obstetrics.
Bold p-values indicate a significant result.
https://doi.org/10.1371/journal.pone.0174300.t003
Table 4. Multivariate logistic regression analysis of the miRNA prediction score modelling chemo-
therapy-resistance (defined as progression/relapse > 6 months, in the clinical cohort (n = 170).
OR 95% CI P-value
Prediction score 0.19 0.05–0.73 0.0152
Age 1.01 0.70–1.47 0.949
FIGO stage
I - - -
II 1 - -
III 1.64 0.29–9.43 0.576
IV 4.73 0.61–36.36 0.136
Histologic type
Serous adenocarcinoma 1 - -
Mucinous adenocarcinoma 0.37 0.03–4.66 0.441
Endometriod adenocarcinoma 2.45 0.26–23.18 0.435
Clear cell adenocarcinoma 12.61 1.27–125.03 0.0303
Macroradical surgery (yes/no) 7.16 2.40–21.35 0.0004
OR = odds ratio, 95%
CI = 95% confidence interval
FIGO = International Federation of Gynecology and Obstetrics.
Bold p-values indicate a significant result.
https://doi.org/10.1371/journal.pone.0174300.t004
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reported to restore sensitivity to Paclitaxel and Carboplatin [28, 34]. Furthermore, one study
found that upregulation and introduction of mimics of the miR-200 family members in the
paclitaxel resistant OVCAR-3/TP cells were unable to restore sensitivity to Paclitaxel and fur-
ther increased resistance to Carboplantin, particularly miR-200c and miR-141 mimic. How-
ever, miR-200c and miR-141 mimics did sensitize MES-OV/TP cells to paclitaxel. They
therefore concluded that restoration of sensitivity, by upregulation and mimics of the miR-200
family members, depended on cell context, as the different cell lines had different expression
levels of the miR-200 family members [35]. In our study miR-200a, miR-200b and miR-200c
showed to be negatively correlated to Carboplatin sensitivity. For Carboplatin alone, miR-370
has shown to promote chemo-sensitivity in endometrioid OC [36]. This is in line with our
findings, where miR-370 showed to be positively correlated to Carboplatin sensitivity. In
Table 5. Multivariate, cox analysis of the miRNA prediction score, predicting survival in the clinical
cohort (n = 170).
HR 95% CI P-value
PFS
Prediction score 0.69 0.40–1.19 0.183
Age 1.08 0.91–1.27 0.391
FIGO stage
I 0.09 0.02–0.34 0.0004
II 0.63 0.26–1.53 0.308
III 0.98 0.56–1.72 0.943
IV 1 - -
Histologic type
Serous adenocarcinoma 1 - -
Mucinous adenocarcinoma 0.94 0.33–2.72 0.913
Endometriod adenocarcinoma 0.28 0.07–1.18 0.082
Clear cell adenocarcinoma 1.86 0.63–5.52 0.262
Macroradical surgery 3.49 2.23–5.45 <0.0001
OS
Prediction score 0.76 0.42–1.40 0.386
Age 1.23 1.03–1.47 0.0202
FIGO stage
I 1 - -
II 3.67 1.04–12.92 0.0431
III 7.41 2.46–22.36 0.0004
IV 8.36 2.44–28.66 0.0007
Histologic type
Serous adenocarcinoma 1 - -
Mucinous adenocarcinoma 2.42 0.95–6.15 0.065
Endometriod adenocarcinoma 0.38 0.09–1.60 0.189
Clear cell carcinoma 2.43 0.82–7.18 0.108
Macroradical surgery 2.63 1.61–4.26 0.0001
HR = hazard ratio, 95%
CI = 95% confidence interval
PFS = progression free survival
OS = overall survival
FIGO = International Federation of Gynecology and Obstetrics.
Bold p-values indicate a significant result.
https://doi.org/10.1371/journal.pone.0174300.t005
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contrast to our findings, where miR-29b has shown to be negatively correlated to Carboplatin
sensitivity, a previous study found overexpression of miR-29a/b/c to sensitize OC cells to Cis-
platin [37]. The full understanding of miRNAs regulation of chemotherapy-resistance in OC
needs much further research. A comparison of the miRNA function found in the current
study and in the literature is given in Table 6. It was previously revealed in an analysis of the
Cancer Genome Atlas that no clear single miRNA signature can predict chemotherapy-sensi-
tivity in patients, addressing the multifactorial nature of drug resistance in OC [38]. Further-
more, it has been demonstrated that some of the ways miRNAs affect drugs resistance could
only be demonstrated in in vitro models, which underscores the importance of using a variety
of models for studying the roles of miRNAs [39]. In the current study we combined informa-
tion of in vitro cell lines response to drugs, and microarray analyses on tumor tissue from OC
patients combined with their clinical information of response to chemotherapy in order to
develop a method for prediction of response to chemotherapeutics. However the conflicting
results of the miRNAs regulation of chemotherapy-resistance found in previous studies, indi-
cate that the function of the miRNAs are still unclear, and might not be specific enough for
detection of resistance, but could also be addressed to the various analyses methods and
designs used in the different studies.
To our best knowledge this is the first study to investigate a global miRNA predictor of che-
motherapy-resistance in OC patients. Although the miRNA predictors were not independent
predictors of chemotherapy-resistance or survival in the primary analyses, a trend was
observed. However we did see that the predictors were significant predictors of chemother-
apy-resistance, when resistance was categorized (progression or death more or less than 6
months). The analysis further showed that patients with residual tumor after primary surgery
had increased risk of progression within the first 6 month after end of chemotherapy, as would
Table 6. Comparison of miRNAs and chemotherapy response in the current study and the literature.
miRNA Response shown in the current study Response shown for OC in the literature
Let-7e Negatively correlated to paclitaxel sensitivity "# in paclitaxel and cisplatin resistant cells
[23]
miR-30c Negatively correlated to paclitaxel sensitivity # in cisplatin + paclitaxel resistant cells [23]
miR-
130a
Negatively correlated to paclitaxel sensitivity # in cisplatin + paclitaxel resistant cells [23]
miR-
200a
Negatively correlated to carboplatin sensitivity • " in carboplatin + paclitaxel sensitive
cells [28]
• " enhanced sensitivity to paclitaxel, but
not cisplatin [40]
miR-
200c
Negatively correlated to carboplatin sensitivity • # in platinum/taxane resistant cells [33]
• " restored carboplatin and paclitaxel
sensitivity [27, 29]
miR-429 Negatively correlated to carboplatin sensitivity • " increased sensitivity to cisplatin [41]
• " in drug sensitive patients [42]
miR-370 Positively correlated to carboplatin sensitivity " promotes carboplatin sensitivity in
endometroid OC [36]
miR-29b Negatively correlated to carboplatin, paclitaxel and
docetaxel sensitivity
• # increased resistance to cisplatin [37]
• " sensitized cells to paclitaxel [43]
miR-27b Negatively correlated to paclitaxel sensitivity " in paclitaxel resistant cell lines [44]
Positive = correlation above 0.25.
Negative = correlation below -0.25.
The arrows symbolize either up-regulation (") or down-regulation (#) of the miRNA.
https://doi.org/10.1371/journal.pone.0174300.t006
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be expected. Preliminary analysis of interaction between the miRNA predictors and marcrora-
dical surgery were performed, and none were observed. Therefor subgroup analysis on
patients with residual tumor was not relevant. Since only six OC cell lines are included in the
NCI60 panel, it might be one of the reasons the predictors failed to show a general significant
result. However, the reasons the miRNA predictors fail to predict OS may also be attributed to
the term survivalpost progression, especially if survivalpost progression is long [45].
The strengths of the current study are the consecutively inclusion of patients, where clinical
information is continuously updated in the Danish Gynaecologic Cancer Database the long
follow-up time, where all patients have been followed for at least five years, and none were lost
to follow-up [4].
The current study was a retrospective validation study of the miRNA-based predictors of
chemotherapy-resistance. The relative small number of patients included in the study should
be noted as a weakness, as well as the number of patients excluded from the current analysis,
which potentially could have biased the interpretation of the current results, and would have
rendered it difficult to apply the results to the general population. However, the group of
excluded patients, due to insufficient tissue material, was comparable to the groups of included
patients in the analysis according to age, FIGO stage, and histologic type. Further the cohort
only included patients from a single center, and resistance was only evaluated on results from
first-line chemotherapy, where patients have a high response rate.
Improvements in treatment of OC with better surgical techniques, new antiangiogenic
drugs and PARP inhibitors has within recent years improved survival, so time to progression
has been prolonged considerably [46–48]. However, the majority will eventually develop resis-
tance, and responses to subsequent treatments are generally short-lived. Therefore prediction
of the potentially most effective second line treatment for those patients who relapse would be
very important. Unfortunately the current developed miRNA based predictors did not demon-
strate to be clinical relevant predictors of chemotherapy-resistance or survival in patients with
OC.
Conclusion
In the current study miRNA based predictors of chemotherapy-resistance were not able to
demonstrate significant associations with resistance to treatment with Carboplatin, Docetaxel
and Paclitaxel in patients with OC. However in secondary analyses the predictors did reflect
relapse more or less than 6 months after end of primary chemotherapy. Larger studies where
subgroup analyses are possible are warranted.
Supporting information
S1 Clinical Data.
(SAV)
Acknowledgments
We are grateful to the Danish CancerBiobank and the Danish Gynecologic Cancer Database
for making tissue and data available for use in the present study. We thank Medical Prognosis
Institute for providing study reagents, and for the conduct of the microarray analyses.
Author Contributions
Conceptualization: KPP CH IJC GWN SK PBJ EH.
MicroRNA and chemotherapy prediction in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174300 March 23, 2017 12 / 15
Data curation: KPP CH MAK AWEG AH EH.
Formal analysis: KPP IJC SK LN.
Funding acquisition: KPP CH SK AH PBJ TJ EH.
Investigation: KPP CH MAK AWEG SK AH.
Methodology: KPP IJC SK PBJ.
Project administration: KPP EH.
Resources: CH SK AH PBJ TJ EH.
Software: IJC SK.
Supervision: KPP CH GWN EH.
Validation: KPP CH IJC SK.
Visualization: KPP CH IJC EH.
Writing – original draft: KPP CH IJC SK EH.
Writing – review & editing: KPP CH MAK IJC GWN SK AH PBJ TJ MRM AWEG LN EH.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016; 66
(1):7–30. Epub 2016/01/09.
2. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 7.2
(16.12.2015). Association of the Nordic Cancer Registries. Danish Cancer Society. http://www.ancr.nu,
accessed on 25.05.2016. [Internet].
3. Sant M, Chirlaque Lopez MD, Agresti R, Sanchez Perez MJ, Holleczek B, Bielska-Lasota M, et al. Sur-
vival of women with cancers of breast and genital organs in Europe 1999–2007: results of the EURO-
CARE-5 study. European journal of cancer (Oxford, England: 1990). 2015. Epub 2015/10/01.
4. Annual Report 2014–2015. Danish Gynecological Cancer Database. Nationwide clinical database for
cancer of the ovaries, uterus and cervix. Lægeforeningens forlag, København. 2015 pp 1–69. ISNN:
1903–0223 (online): http://dgcg.dk/images/rsrapport_DGCD_2014-15.pdf [Internet]. 2015.
5. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M. Systematic review of first-line
chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian can-
cer. Gynecologic oncology. 2002; 85(1):71–80. Epub 2002/04/02. https://doi.org/10.1006/gyno.2001.
6552 PMID: 11925123
6. Weinberg LE, Rodriguez G, Hurteau JA. The role of neoadjuvant chemotherapy in treating advanced
epithelial ovarian cancer. Journal of surgical oncology. 2010; 101(4):334–43. Epub 2010/02/27. https://
doi.org/10.1002/jso.21482 PMID: 20187069
7. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future direc-
tions. Seminars in oncology. 2009; 36(2):112–25. Epub 2009/04/01. https://doi.org/10.1053/j.
seminoncol.2008.12.003 PMID: 19332246
8. Chien JR, Aletti G, Bell DA, Keeney GL, Shridhar V, Hartmann LC. Molecular pathogenesis and thera-
peutic targets in epithelial ovarian cancer. Journal of cellular biochemistry. 2007; 102(5):1117–29. Epub
2007/09/21. https://doi.org/10.1002/jcb.21552 PMID: 17879946
9. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nature reviews Genetics.
2004; 5(7):522–31. Epub 2004/06/24. https://doi.org/10.1038/nrg1379 PMID: 15211354
10. Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. The New England journal of medicine. 2008;
359(25):2720–2. Epub 2008/12/19. https://doi.org/10.1056/NEJMe0808667 PMID: 19092157
11. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. The
Lancet Oncology. 2012; 13(6):e249–58. Epub 2012/06/02. https://doi.org/10.1016/S1470-2045(12)
70073-6 PMID: 22652233
12. Langhe R. microRNA and Ovarian Cancer. Advances in experimental medicine and biology. 2015;
889:119–51. Epub 2015/12/15. https://doi.org/10.1007/978-3-319-23730-5_8 PMID: 26659000
MicroRNA and chemotherapy prediction in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174300 March 23, 2017 13 / 15
13. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human
ovarian cancer. Cancer research. 2007; 67(18):8699–707. Epub 2007/09/19. https://doi.org/10.1158/
0008-5472.CAN-07-1936 PMID: 17875710
14. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations
deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Acad-
emy of Sciences of the United States of America. 2008; 105(19):7004–9. Epub 2008/05/07. https://doi.
org/10.1073/pnas.0801615105 PMID: 18458333
15. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, et al. MicroRNA expression profiles in serous ovar-
ian carcinoma. Clinical cancer research: an official journal of the American Association for Cancer
Research. 2008; 14(9):2690–5. Epub 2008/05/03.
16. Danish Cancer Biobank, www.cancerbiobank.dk www.cancerbiobank.dk: www.cancerbiobank.dk;
2015 [cited 2015].
17. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort
of eight million persons. Danish medical bulletin. 2006; 53(4):441–9. Epub 2006/12/08. PMID:
17150149
18. Developmental Therapeutics Program, U.S. National Cancer Institute [updated 06.09.2015]. https://dtp.
cancer.gov/.
19. Winther M, Knudsen S, Dahlgaard J, Jensen T, Hansen A, Jensen PB, et al. Clinical Impact of a Novel
MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer. PloS one. 2016; 11(2):
e0148070. Epub 2016/02/18. https://doi.org/10.1371/journal.pone.0148070 PMID: 26885979
20. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of
the American statistical association. 1999; 94(446):496–509.
21. Knudsen S, Hother C, Gronbaek K, Jensen T, Hansen A, Mazin W, et al. Development and blind clinical
validation of a microRNA based predictor of response to treatment with R-CHO(E)P in DLBCL. PloS
one. 2015; 10(2):e0115538. Epub 2015/02/19. https://doi.org/10.1371/journal.pone.0115538 PMID:
25692889
22. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et al. MicroRNA microarray identifies
Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer research.
2008; 68(24):10307–14. Epub 2008/12/17. https://doi.org/10.1158/0008-5472.CAN-08-1954 PMID:
19074899
23. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecologic oncology. 2008; 111(3):478–86. Epub 2008/10/01. https://doi.org/10.
1016/j.ygyno.2008.08.017 PMID: 18823650
24. Prahm KP, Novotny GW, Hogdall C, Hogdall E. Current status on microRNAs as biomarkers for ovarian
cancer. APMIS: acta pathologica, microbiologica, et immunologica Scandinavica. 2016; 124(5):337–
55. Epub 2016/01/27. https://doi.org/10.1111/apm.12514 PMID: 26809719
25. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-
7 microRNA family. Cell. 2005; 120(5):635–47. Epub 2005/03/16. https://doi.org/10.1016/j.cell.2005.01.
014 PMID: 15766527
26. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small
cell lung tumor development by the let-7 microRNA family. Proceedings of the National Academy of Sci-
ences of the United States of America. 2008; 105(10):3903–8. Epub 2008/03/01. https://doi.org/10.
1073/pnas.0712321105 PMID: 18308936
27. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK. MicroRNA-200c mitigates invasive-
ness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Molecular cancer ther-
apeutics. 2009; 8(5):1055–66. Epub 2009/05/14. https://doi.org/10.1158/1535-7163.MCT-08-1046
PMID: 19435871
28. Mateescu B, Batista L, Cardon M, Gruosso T, de Feraudy Y, Mariani O, et al. miR-141 and miR-200a
act on ovarian tumorigenesis by controlling oxidative stress response. Nature medicine. 2011; 17
(12):1627–35. Epub 2011/11/22. https://doi.org/10.1038/nm.2512 PMID: 22101765
29. Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, et al. MiR-200c and HuR in ovar-
ian cancer. BMC cancer. 2013; 13:72. Epub 2013/02/12. https://doi.org/10.1186/1471-2407-13-72
PMID: 23394580
30. Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer research. 2009; 69(16):6704–12. Epub 2009/08/06. https://doi.org/10.
1158/0008-5472.CAN-09-1298 PMID: 19654291
31. Ceppi P, Mudduluru G, Kumarswamy R, Rapa I, Scagliotti GV, Papotti M, et al. Loss of miR-200c
expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung
MicroRNA and chemotherapy prediction in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174300 March 23, 2017 14 / 15
cancer. Molecular cancer research: MCR. 2010; 8(9):1207–16. Epub 2010/08/11. https://doi.org/10.
1158/1541-7786.MCR-10-0052 PMID: 20696752
32. Castilla MA, Moreno-Bueno G, Romero-Perez L, Van De Vijver K, Biscuola M, Lopez-Garcia MA, et al.
Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. The
Journal of pathology. 2011; 223(1):72–80. Epub 2010/12/03. https://doi.org/10.1002/path.2802 PMID:
21125666
33. Leskela S, Leandro-Garcia LJ, Mendiola M, Barriuso J, Inglada-Perez L, Munoz I, et al. The miR-200
family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response
and progression-free survival in ovarian cancer patients. Endocrine-related cancer. 2011; 18(1):85–95.
Epub 2010/11/06. https://doi.org/10.1677/ERC-10-0148 PMID: 21051560
34. van Jaarsveld MT, Helleman J, Boersma AW, van Kuijk PF, van Ijcken WF, Despierre E, et al. miR-141
regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene. 2013; 32
(36):4284–93. Epub 2012/10/10. https://doi.org/10.1038/onc.2012.433 PMID: 23045278
35. Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates
sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells.
Molecular oncology. 2015; 9(8):1678–93. Epub 2015/05/31. https://doi.org/10.1016/j.molonc.2015.04.
015 PMID: 26025631
36. Chen XP, Chen YG, Lan JY, Shen ZJ. MicroRNA-370 suppresses proliferation and promotes endome-
trioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG. Cancer letters. 2014; 353
(2):201–10. Epub 2014/07/27. https://doi.org/10.1016/j.canlet.2014.07.026 PMID: 25063739
37. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC, et al. Downregulation of miR-29 contributes to
cisplatin resistance of ovarian cancer cells. International journal of cancer Journal international du can-
cer. 2014; 134(3):542–51. Epub 2013/08/02. https://doi.org/10.1002/ijc.28399 PMID: 23904094
38. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, et al. Integrated
analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade
serous ovarian carcinoma. PloS one. 2012; 7(3):e34546. Epub 2012/04/06. https://doi.org/10.1371/
journal.pone.0034546 PMID: 22479643
39. Vecchione A, Belletti B, Lovat F, Volinia S, Chiappetta G, Giglio S, et al. A microRNA signature defines
chemoresistance in ovarian cancer through modulation of angiogenesis. Proceedings of the National
Academy of Sciences of the United States of America. 2013; 110(24):9845–50. Epub 2013/05/24.
https://doi.org/10.1073/pnas.1305472110 PMID: 23697367
40. Liu N, Zhong L, Zeng J, Zhang X, Yang Q, Liao D, et al. Upregulation of microRNA-200a associates
with tumor proliferation, CSCs phenotype and chemosensitivity in ovarian cancer. Neoplasma. 2015; 62
(4):550–9. Epub 2015/05/23. https://doi.org/10.4149/neo_2015_066 PMID: 25997962
41. Wang L, Mezencev R, Svajdler M, Benigno BB, McDonald JF. Ectopic over-expression of miR-429
induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing
ovarian cancer cells. Gynecologic oncology. 2014; 134(1):96–103. Epub 2014/05/08. https://doi.org/10.
1016/j.ygyno.2014.04.055 PMID: 24802724
42. Zhao HM, Wei W, Sun YH, Gao JH, Wang Q, Zheng JH. MicroRNA-9 promotes tumorigenesis and
mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells. Tumour biology: the journal of
the International Society for Oncodevelopmental Biology and Medicine. 2015; 36(9):6867–73. Epub
2015/04/08.
43. Sugio A, Iwasaki M, Habata S, Mariya T, Suzuki M, Osogami H, et al. BAG3 upregulates Mcl-1 through
downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecologic oncol-
ogy. 2014; 134(3):615–23. Epub 2014/07/06. https://doi.org/10.1016/j.ygyno.2014.06.024 PMID:
24992675
44. Li Z, Hu S, Wang J, Cai J, Xiao L, Yu L, et al. MiR-27a modulates MDR1/P-glycoprotein expression by
targeting HIPK2 in human ovarian cancer cells. Gynecologic oncology. 2010; 119(1):125–30. Epub
2010/07/14. https://doi.org/10.1016/j.ygyno.2010.06.004 PMID: 20624637
45. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival.
Journal of the National Cancer Institute. 2009; 101(23):1642–9. Epub 2009/11/12. https://doi.org/10.
1093/jnci/djp369 PMID: 19903805
46. Ledermann JA, El-Khouly F. PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment
decisions. British journal of cancer. 2015; 113 Suppl 1:S10–6. Epub 2015/12/17.
47. Garcia A, Singh H. Bevacizumab and ovarian cancer. Therapeutic advances in medical oncology.
2013; 5(2):133–41. Epub 2013/03/02. https://doi.org/10.1177/1758834012467661 PMID: 23450196
48. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy
in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England journal of medicine. 2016. Epub
2016/10/09. doi: 10.1056/NEJMoa1611310. PMID: 27717299.
MicroRNA and chemotherapy prediction in ovarian cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0174300 March 23, 2017 15 / 15
